Department of Biochemistry and Molecular Biology, Army Medical College, Rawalpindi, Pakistan.
J Pak Med Assoc. 2024 Feb;74(2):310-314. doi: 10.47391/JPMA.9254.
To determine the association of serum interleukin-12 levels with disease progression in active rheumatoid arthritis patients on oral conventional synthetic disease-modifying anti-rheumatic drugs.
The case-control study was conducted at the Army Medical College, Rawalpindi, in collaboration with the Pak Emirates Military Hospital, Rawalpindi, Pakistan, from January to December 2022, and comprised rheumatoid arthritis patients or either gender aged 18-75 years who were placed in group I, while group II comprised healthy controls. Demographic and clinical data was noted, and 2ml blood samples were drawn from each subject. The serum was separated and analysed using sandwich enzyme-linked immunosorbent assay to quantify serum interleukin-12 levels. Data was analysed using SPSS 22.
Of the 150 subjects, 75(50%) were in group I; 27(36%) males and 48(64%) females with overall mean age 45.70±11.70 years. There were 75(50%) subjects in group II; 37(49.3%) males and 38(50.7%) females with overall mean age 31.70±7.70 years. Serum interleukin-12, erythrocyte sedimentation rate and C-reactive proteinquantitative levels were significantly higher in group I compared to group II (p<0.05). Smoking, positive family history of rheumatoid arthritis in a first-degree relative and history of consanguinity were identified as risk factors though they were not statistically significant (p>0.05). In group I (n=75), out of total study subjects, only 55(73.3%) cases belonged to the predominant castes, namely Awan, Rajput, Pathan, Araeen, Bhatti, Malik, Mughal, Sudhan, Chaudary, and Jutt. These individuals showed significantly higher mean serum interleukin-12 levels compared to patients of other castes in the same group.
Mean serum interleukin-12 levels were higher in rheumatoid arthritis patients despite being on oral conventional synthetic disease-modifying anti-rheumatic drugs.
确定血清白细胞介素-12 水平与口服常规合成疾病修饰抗风湿药物治疗的活动期类风湿关节炎患者疾病进展的关系。
本病例对照研究于 2022 年 1 月至 12 月在巴基斯坦拉瓦尔品第的陆军医学院与 Pak Emirates Military Hospital 合作进行，纳入的研究对象为 18-75 岁的男女类风湿关节炎患者，分为 I 组，同时纳入健康对照组（II 组）。记录患者的人口统计学和临床数据，并采集每位受试者 2ml 血样。采用夹心酶联免疫吸附试验分离并分析血清，以定量血清白细胞介素-12 水平。采用 SPSS 22 对数据进行分析。
在 150 名受试者中，75 名（50%）为 I 组，其中 27 名（36%）为男性，48 名（64%）为女性，平均年龄为 45.70±11.70 岁；75 名（50%）为 II 组，其中 37 名（49.3%）为男性，38 名（50.7%）为女性，平均年龄为 31.70±7.70 岁。与 II 组相比，I 组的血清白细胞介素-12、红细胞沉降率和 C 反应蛋白定量水平显著更高（p<0.05）。吸烟、一级亲属类风湿关节炎阳性家族史和近亲结婚被确定为危险因素，但无统计学意义（p>0.05）。在 I 组（n=75）中，只有 55 名（73.3%）患者属于主要种姓，即 Awan、Rajput、Pathan、Araeen、Bhatti、Malik、Mughal、Sudhan、Chaudary 和 Jutt。与同一组中其他种姓的患者相比，这些个体的血清白细胞介素-12 水平显著更高。
尽管接受口服常规合成疾病修饰抗风湿药物治疗，但类风湿关节炎患者的血清白细胞介素-12 水平仍较高。
